Complement C3 is a novel plasma clot component with anti-fibrinolytic properties

Diabetes and Vascular Disease Research

Volumn 9, Issue 3, 2012, Pages 216-225

  Howes, Joanna Marie ^a,c   Richardson, Victoria R ^a   Smith, Kerrie A ^a,b   Schroeder, Verena ^a,d   Somani, Riyaz ^a   Shore, Anna ^a   Hess, Katharina ^a,e   Ajjan, Ramzi ^a,b   Pease, Richard J ^a,b   Keen, Jeffrey N ^b   Standeven, Kristina F ^a,b   Carter, Angela M ^a,b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF BERN   (Switzerland)

^e UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Complement C3; fibrin; fibrinolysis; inflammation; thrombosis

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT FACTOR H; FIBRIN; FIBRINOGEN;

ADULT; ARTICLE; BINDING AFFINITY; BLOOD CLOT; BLOOD CLOT LYSIS; CARDIOVASCULAR DISEASE; COMPLEMENT SYSTEM; CONCENTRATION RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; FEMALE; FIBRINOLYSIS; HUMAN; IMMUNE SYSTEM; IN VITRO STUDY; INFLAMMATION; MALE; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PLASMA; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; PROTEOMICS; SERUM; SURFACE PLASMON RESONANCE; THROMBOSIS; TURBIDIMETRY;

COMPLEMENT C3; COMPLEMENT FACTOR H; FEMALE; FIBRIN; FIBRINOGEN; FIBRINOLYSIS; HUMANS; MALE; PLASMA; THROMBOSIS;

EID: 84859995396     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164111432788     Document Type: Article

References (42)

1. Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, Kostis JB, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005; 294: 1799-1809. (Pubitemid 41434626)
2. Thogersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, Huhtasaari F, et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998; 98: 2241-2247. (Pubitemid 28533841)
3. Fatah K, Hamsten A, Blomback B and Blomback M. Fibrin gel network characteristics and coronary heart disease: relations to plasma fibrinogen concentration, acute phase protein, serum lipoproteins and coronary atherosclerosis. Thromb Haemost 1992; 68: 130-135.
4. Fatah K, Silveira A, Tornvall P, Karpe F, Blomback M and Hamsten A. Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age. Thromb Haemost 1996; 76: 535-540. (Pubitemid 26372007)
5. Mills JD, Ariens RA, Mansfield MW and Grant PJ. Altered fibrin clot structure in the healthy relatives of patients with premature coronary artery disease. Circulation 2002; 106: 1938-1942. (Pubitemid 35176298)
6. Bhasin N, Ariens RA, West RM, Parry DJ, Grant PJ and Scott DJ. Altered fibrin clot structure and function in the healthy first-degree relatives of subjects with intermittent claudication. J Vasc Surg 2008; 48: 1497-1503.
7. Carter AM, Cymbalista CM, Spector TD and Grant PJ. Heritability of clot formation, morphology, and lysis: the EuroCLOT study. Arterioscler Thromb Vasc Biol 2007; 27: 2783-2789. (Pubitemid 350158937)
8. Carr ME. Fibrin formed in plasma is composed of fibers more massive than those formed from purified fibrinogen. Thromb Haemost 1988; 59: 535-539.
9. Muszbek L, Adany R and Mikkola H. Novel aspects of blood coagulation factor XIII. I. Structure, distribution, activation, and function. Crit Rev Clin Lab Sci 1996; 33: 357-421. (Pubitemid 26405375)
10. Scott EM, Ariens RA and Grant PJ. Genetic and environmental determinants of fibrin structure and function: relevance to clinical disease. Arterioscler Thromb Vasc Biol 2004; 24: 1558-1566. (Pubitemid 39180877)
11. Gage MC, Keen JN, Buxton AT, Bedi MK and Findlay JB. Proteomic analysis of IgE-mediated secretion by LAD2 mast cells. J Proteome Res 2009; 8: 4116-4125.
12. Ajjan R, Grant PJ, Futers TS, Brown JM, Cymbalista CM, Boothby M and Carter AM. Complement C3 and C-reactive protein levels in patients with stable coronary artery disease. Thromb Haemost 2005; 94: 1048-1053. (Pubitemid 41645948)
13. Jessen TE, Barkholt V and Welinder KG. A simple alternative pathway for hemolytic assay of human complement component C3 using methylamine-treated plasma. J Immunol Methods 1983; 60: 89-100. (Pubitemid 13058311)
14. Carter AM, Catto AJ and Grant PJ. Association of the alpha-fibrinogen Thr312Ala polymorphism with poststroke mortality in subjects with atrial fibrillation. Circulation 1999; 99: 2423-2426. (Pubitemid 29218238)
15. Tack BD and Prahl JW. Third component of human complement: purification from plasma and physicochemical characterization. Biochemistry 1976; 15: 4513-4521.
16. Standeven KF, Grant PJ, Carter AM, Scheiner T, Weisel JW and Ariens RA. Functional analysis of the fibrinogen alpha Thr312Ala polymorphism: effects on fibrin structure and function. Circulation 2003; 107: 2326-2330. (Pubitemid 36578503)
17. Smith KA, Adamson PJ, Pease RJ, Brown JM, Balmforth AJ, Cordell PA, et al. Interactions between factor XIII and the alphaC region of fibrinogen. Blood 2011; 117: 3460-3468.
18. Dennis Jr G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 2003; 4: 3.
19. Huang DW, Sherman BT and Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4: 44-57.
20. Rijken DC, Dirkx SP, Luider TM and Leebeek FW. Hepatocyte-derived fibrinogen-related protein-1 is associated with the fibrin matrix of a plasma clot. Biochem Biophys Res Commun 2006; 350: 191-194. (Pubitemid 44466591)
21. Walker JB, Binette TM, Mackova M, Lambkin GR, Mitchell L and Bajzar L. Proteolytic cleavage of carboxypeptidase N markedly increases its antifibrinolytic activity. J Thromb Haemost 2008; 6: 848-855. (Pubitemid 351524547)
22. Krem MM and Di Cera E. Evolution of enzyme cascades from embryonic development to blood coagulation. Trends Biochem Sci 2002; 27: 67-74. (Pubitemid 34164321)
23. Marshall J, Kupchak P, Zhu W, Yantha J, Vrees T, Furesz S, et al. Processing of serum proteins underlies the mass spectral fingerprinting of myocardial infarction. J Proteome Res 2003; 2: 361-372. (Pubitemid 36988415)
24. Donahue MP, Rose K, Hochstrasser D, Vonderscher J, Grass P, Chibout SD, et al. Discovery of proteins related to coronary artery disease using industrial-scale proteomics analysis of pooled plasma. Am Heart J 2006; 152: 478-485. (Pubitemid 44233432)
25. Distelmaier K, Adlbrecht C, Jakowitsch J, Winkler S, Dunkler D, Gerner C, et al. Local complement activation triggers neutrophil recruitment to the site of thrombus formation in acute myocardial infarction. Thromb Haemost 2009; 102: 564-572.
26. Muscari A, Bozzoli C, Puddu GM, Sangiorgi Z, Dormi A, Rovinetti C, et al. Association of serum C3 levels with the risk of myocardial infarction. Am J Med 1995; 98: 357-364.
27. Szeplaki G, Prohaszka Z, Duba J, Rugonfalvi-Kiss S, Karadi I, Kokai M, et al. Association of high serum concentration of the third component of complement (C3) with pre-existing severe coronary artery disease and new vascular events in women. Atherosclerosis 2004; 177: 383-389. (Pubitemid 39505272)
28. Onat A, Uzunlar B, Hergenc G, Yazici M, Sari I, Uyarel H, et al. Cross-sectional study of complement C3 as a coronary risk factor among men and women. Clin Sci (Lond) 2005; 108: 129-135. (Pubitemid 40175406)
29. Carter AM, Prasad UK and Grant PJ. Complement C3 and C-reactive protein in male survivors of myocardial infarction. Atherosclerosis 2009; 203: 538-543.
30. Moskowitz KA, Kudryk B and Coller BS. Fibrinogen coating density affects the conformation of immobilized fibrinogen: implications for platelet adhesion and spreading. Thromb Haemost 1998; 79: 824-831. (Pubitemid 28163862)
31. Lishko VK, Burke T and Ugarova T. Antiadhesive effect of fibrinogen: a safeguard for thrombus stability. Blood 2007; 109: 1541-1549. (Pubitemid 46239587)
32. Schroeder V, Carter AM, Dunne J, Mansfield MW and Grant PJ. Proinflammatory and hypofibrinolytic phenotype in healthy first-degree relatives of patients with type 2 diabetes. J Thromb Haemost 2010; 8: 2080-2082.
33. Hess K, Alzahrani SH, Mathai M, Schroeder V, Carter AM, Howell G, et al. A novel mechanism for hypofibrinolysis in diabetes: the role of complement C3. Diabetologia 2011. Epub ahead of print. DOI: 10.1007/s00125-011-2301-7.
34. Shats-Tseytlina EA, Nair CH and Dhall DP. Complement activation: a new participant in the modulation of fibrin gel characteristics and the progression of atherosclerosis? Blood Coagul Fibrinolysis 1994; 5: 529-535. (Pubitemid 24301573)
35. Krarup A, Wallis R, Presanis JS, Gal P and Sim RB. Simultaneous activation of complement and coagulation by MBL-associated serine protease 2. PLoS ONE 2007; 2: e623.
36. Taylor FB Jr and Muller-Eberhard HJ. Qualitative description of factors involved in the retraction and lysis of dilute whole blood clots and in the aggregation and retraction of platelets. J Clin Invest 1970; 49: 2068-2085.
37. Wuillemin WA, Minnema M, Meijers JC, Roem D, Eerenberg AJ, Nuijens JH, et al. Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: major role for C1-inhibitor. Blood 1995; 85: 1517-1526.
38. Presanis JS, Hajela K, Ambrus G, Gal P and Sim RB. Differential substrate and inhibitor profiles for human MASP-1 and MASP-2. Mol Immunol 2004; 40: 921-929. (Pubitemid 38077036)
39. Myles T, Nishimura T, Yun TH, Nagashima M, Morser J, Patterson AJ, et al. Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. J Biol Chem 2003; 278: 51059-51067. (Pubitemid 38020340)
40. Sun H, Ringdahl U, Homeister JW, Fay WP, Engleberg NC, Yang AY, et al. Plasminogen is a critical host pathogenicity factor for group A streptococcal infection. Science 2004; 305: 1283-1286. (Pubitemid 39129231)
41. Marchi R, Nagaswami C and Weisel JW. Fibrin formation and lysis studies in dengue virus infection. Blood Coagul Fibrinolysis 2009; 20: 575-582.
42. Beaufort N, Wojciechowski P, Sommerhoff CP, Szmyd G, Dubin G, Eick S, et al. The human fibrinolytic system is a target for the staphylococcal metalloprotease aureolysin. Biochem J 2008; 410: 157-165. (Pubitemid 351300335)